The roadmap below provides a high level summary of our planned activity over the next 12 months. We'll update the roadmap as we have new information. Clinical trials will be subject to IRB & regulatory approval. Our primary objective will be raising the capital required to ensure the trials have funds to proceed.
1 year from starting DNKO LLC we aim to be in human Phase I trials
Brain cancer and its treatment has historically not been a profitable enterprise. Few companies have ventured into, or if they did, few have remained in this field, (although that could be changing).
"The world’s largest pharmaceutical companies, skilled at creating drugs for the heart, lungs and joints, couldn’t find the same success in the brain, leading them to either pull back or shutter development over the last decade"
There are only 23 drugs approved for brain cancer that when used as pre- or post surgical adjuvants, have not made much of an impact on survival following resection or even LITT. Statistically, according to the American Cancer Society there are 24,810 malignant tumors of the brain or spinal cord diagnosed in the USA in 2023 that includes both adults and children, of which 18,990 people will die. Survival rates do depend on the kind of brain cancer and age of the patient. For example, for Glioblastoma, 5-year survivals are 22%, 9%, and 6% for age ranges, 20-44 yrs, 45-54 yrs, and 55-64 yrs, respectively.
From a business perspective, according to Fortune business, the brain cancer drug market has been stagnant at ~$1 Billion from 2018 to 2023, (basically 25,000 patients at $40,000 per surgical treatment) while other cancer markets have risen with some in the $40-50 Billion range, expected to increase to $80 Billion by 2029, in part because of the higher prevalence and opportunities for longer term adjuvant therapeutics.
Thus, brain cancer has traditionally been underserved, is exceedingly difficult to treat, and has had virtually no curable successes. As can be imagined, treating brain cancer is not a sustainable profitable market. But a lack of profit does not put us off, in fact, it spurs us on to change the paradigm.
Our ethos is to be less concerned about profits and statistics and be more concerned about patients, their families and their clinicians, because, if a person has brain cancer, it's a 1 in 1, and no amount of profit in someone else's pocket is going to (currently) cure them.
If LITT + LTSL-Dox can cure just one person, it will be worth it. We are therefore seeking mainly philanthropic funding and foundation grants and donations from like minded advocates and resonant souls.
LITT + LTSL-Dox just needs testing.
It's time to invest in people.